Tomotake Shirono

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki et al. · Cancers · 2020 · 75 citations · Full text

Effects of in‐hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease

Shunji Koya, Takumi Kawaguchi, Ryuki Hashida et al. · Hepatology Research · 2016 · 69 citations · Full text

Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study

Masahito Nakano, Masatoshi Tanaka, Ryoko Kuromatsu et al. · Cancer Medicine · 2015 · 63 citations · Full text

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose et al. · Cancers · 2020 · 63 citations · Full text

Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis

Shigeo Shimose, Takumi Kawaguchi, Masatoshi Tanaka et al. · Oncology Letters · 2020 · 61 citations · Full text